Progressive Supranuclear Palsy (PSP) represents a significant unmet medical need in the neurodegenerative disease space, with a current global market estimated at approximately $250 million and projected to reach $1.2 billion by 2035. As a rare 4R-tauopathy characterized by tau protein aggregation in the basal ganglia and brainstem, PSP has historically received less investment than more prevalent neurodegenerative disorders. However, recent advances in tau-targeted therapeutics and growing recognition of the disease's impact have driven increased pharmaceutical interest and investment in the field. [1]
PSP is a rare neurodegenerative disorder affecting approximately 10-20 per 100,000 individuals worldwide, with typical onset in the sixth or seventh decade of life. The disease is characterized by vertical gaze palsy, postural instability with falls, bradykinesia, and cognitive decline. PSP is classified as a 4R-tauopathy, meaning it involves the accumulation of the 4-repeat isoform of tau protein, distinguishing it from Alzheimer's disease (which has a mix of 3R and 4R tau) and creating unique therapeutic targeting opportunities. [2]
The PSP investment landscape encompasses: [3]
Investment in PSP R&D has historically lagged behind Alzheimer's and Parkinson's disease, but recent Phase 2 successes and increased understanding of tauopathies have catalyzed new investment. The relative rarity of PSP creates challenges for clinical trial recruitment but also represents opportunities for orphan drug designations and accelerated approval pathways. [4]
Tau immunotherapy represents the most advanced therapeutic approach for PSP: [5]
Semorinemab (TAK-920/ABBV-8E12): AbbVie/Avid Radiopharmaceuticals' anti-tau antibody targeting the N-terminal region of tau. The Phase 2 LAVENDER trial (NCT02985879) demonstrated significant reduction in tau PET signal and slower disease progression in PSP patients. This represents one of the first positive signals in PSP tau immunotherapy [1][2].
Elli202: Eli Lilly's anti-tau antibody in Phase 1/2 development for PSP. The trial demonstrated antibody generation and biomarker response, with ongoing Phase 2 evaluation [3].
BIIB088 (Biotene): Biogen's anti-tau antibody, though primary development has focused on Alzheimer's disease, the company has explored PSP indications [4].
ACI-35 (Axon Neuroscience): Liposome-based tau phosphorylation-dependent vaccine targeting phosphorylated tau. Phase 1b results showed immune response in Alzheimer's patients, with ongoing evaluation for PSP [5].
Preventing tau protein misfolding and aggregation is a key therapeutic strategy: [6]
LMTM (Leuco-methylthioninium bishydromethanesulfonate): TauRx Therapeutics' methylene blue derivative has been evaluated in multiple tauopathy trials including PSP. The mechanism involves inhibition of tau aggregation through interaction with tau's hexapeptide motifs [6].
Davunetide (AL-108): Allon Therapeutics' intranasal peptide targeting tau phosphorylation and microtubule stabilization. Completed Phase 2 trials in PSP [7].
Several neuroprotective strategies are in development for PSP: [7]
Coenzyme Q10 (CoQ10): Ubiquinol supplementation for mitochondrial dysfunction in PSP. Multiple small trials have suggested potential benefit, though large-scale confirmatory trials are needed [8].
Lithium: Mood stabilizer with neuroprotective properties through GSK-3β inhibition. Observational studies suggest potential benefit in PSP, but controlled trials have shown mixed results [9].
N-acetylcysteine (NAC): Antioxidant and glutamate modulator. The N-AC trial (NCT02424795) evaluated NAC in PSP with mixed results [10].
Current symptomatic management remains limited: [8]
| Mechanism | Development Stage | Development Focus | [9]
|-----------|-------------------|-------------------| [10]
| Tau immunotherapy | Phase 2-3 | Active and passive immunization | [11]
| Tau aggregation inhibitors | Phase 2 | Small molecule inhibitors | [12]
| Neuroprotection | Phase 2-3 | Mitochondrial, antioxidant | [13]
| Symptomatic | Phase 4 | Dopaminergic, symptomatic |
| Gene therapy | Preclinical | AAV-based approaches |
| Biomarkers | Clinical | PET, CSF, blood-based |
Several significant trials are active in PSP:
Modern PSP clinical trials incorporate several innovations:
Several approaches have not succeeded in PSP:
PSP has historically received a small fraction of neurodegenerative disease investment:
| Source | Annual Investment | Focus |
|---|---|---|
| Pharmaceutical industry | $100-200M | Drug development |
| NIH/NINDS | $30-50M | Basic science, trials |
| Private foundations | $20-40M | Research, patient support |
| Venture capital | $50-100M | Biotech companies |
Relative to Alzheimer's disease (4,903 trials) and Parkinson's disease (4,606 trials), PSP (154 trials) remains significantly underinvested:
| Disease | Trial Count | Investment Level |
|---|---|---|
| Alzheimer's | 4,903 | High |
| Parkinson's | 4,606 | High |
| ALS | 1,568 | Moderate |
| FTD | 380 | Moderate |
| PSP | 154 | Low |
| CBD | 60 | Low |
Trevillya et al. Semorinemab in PSP (2024). 2024. ↩︎
Biogen Tau Pipeline (2024). 2024. ↩︎
Kontsekova et al. ACI-35 vaccine (2022). 2022. ↩︎
Wischik et al. LMTM in tauopathies (2020). 2020. ↩︎
Gold et al. Davunetide in PSP (2015). 2015. ↩︎
Stamelou et al. CoQ10 in PSP (2018). 2018. ↩︎
Mathews et al. Lithium in PSP (2021). 2021. ↩︎
Schöll et al. Tau PET in PSP (2023). 2023. ↩︎
Khalil et al. Neurofilament light chain in PSP (2023). 2023. ↩︎